Cargando…

Ixekizumab provides persistent improvements in health‐related quality of life and the sexual impact associated with moderate‐to‐severe genital psoriasis in adult patients during a 52‐week, randomised, placebo‐controlled, phase 3 clinical trial

Detalles Bibliográficos
Autores principales:	Ryan, C., Guenther, L., Foley, P., Weisman, J., Burge, R.T., Gallo, G., See, K., McKean‐Matthews, M., Bertram, C.C., Merola, J.F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299771/ https://www.ncbi.nlm.nih.gov/pubmed/34812561 http://dx.doi.org/10.1111/jdv.17836

Ejemplares similares

Ixekizumab Results in Persistent Clinical Improvement in Moderateto-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial
por: GUENTHER, Lyn, et al.
Publicado: (2020)

Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis
por: Hawkes, Jason E., et al.
Publicado: (2021)

Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
por: Elewski, Boni E., et al.
Publicado: (2022)

Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate‐to‐severe genital psoriasis
por: Merola, J.F., et al.
Publicado: (2020)

Psoriasis Severity Assessment Combining Physician and Patient Reported Outcomes: The Optimal Psoriasis Assessment Tool
por: Leonardi, Craig, et al.
Publicado: (2021)

An Analysis of Patient-reported Outcomes in IXORA-S: Comparing Ixekizumab and Ustekinumab over 52 Weeks in Moderate-to-severe Psoriasis
por: PUIG, Lluís, et al.
Publicado: (2020)

Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)
por: Wasel, Norman, et al.
Publicado: (2020)

Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program
por: Gottlieb, Alice B., et al.
Publicado: (2023)

Clinical outcomes at 1 year in early Psoriasis Area and Severity Index responders compared with non‐responders: Subgroup analysis of UNCOVER‐3 trial
por: Rosmarin, D., et al.
Publicado: (2021)

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial
por: Blauvelt, A., et al.
Publicado: (2020)

A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Erythrodermic psoriasis after discontinuation of ixekizumab
por: Potter, Kathryn Anne, et al.
Publicado: (2017)

Ixekizumab 80 mg Every 2 Weeks Treatment Beyond Week 12 for Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis
por: Morita, Akimichi, et al.
Publicado: (2021)

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis
por: Blauvelt, A., et al.
Publicado: (2017)

Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52‐week, open‐label, phase 3 study (UNCOVER‐J)
por: Saeki, Hidehisa, et al.
Publicado: (2016)

Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry
por: Lockshin, Benjamin, et al.
Publicado: (2021)

A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
por: Kirkham, Bruce W., et al.
Publicado: (2023)

Toxoplasmosis in a patient receiving ixekizumab for psoriasis
por: Lobo, Yolanka, et al.
Publicado: (2020)

Ixekizumab May Improve Renal Function in Psoriasis
por: Amoruso, Giuseppe Fabrizio, et al.
Publicado: (2021)

Onset of vitiligo in a psoriasis patient on ixekizumab
por: Marasca, Claudio, et al.
Publicado: (2021)

Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study
por: Li, Ying, et al.
Publicado: (2022)

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
por: Dougados, Maxime, et al.
Publicado: (2020)

Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52‐Week, Randomized, Controlled Trial
por: Walsh, Jessica A., et al.
Publicado: (2022)

Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab
por: Blauvelt, Andrew, et al.
Publicado: (2020)

Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program
por: Gulliver, Wayne, et al.
Publicado: (2022)

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials
por: Leonardi, Craig, et al.
Publicado: (2020)

The Successful Treatment of a Case of Linear Psoriasis with Ixekizumab
por: Ghoneim, Sara, et al.
Publicado: (2017)

Emerging targeted therapies for plaque psoriasis – impact of ixekizumab
por: Kazemi, Tiana, et al.
Publicado: (2017)

Efficacy and safety of ixekizumab in Chinese patients with plaque psoriasis
por: Huang, He, et al.
Publicado: (2023)

Ixekizumab for the Treatment of Acrodermatitis Continua of Hallopeau and Inverse Psoriasis
por: Xia, Rui Yuan, et al.
Publicado: (2023)

Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks
por: Marzo-Ortega, Helena, et al.
Publicado: (2020)

Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study
por: Smolen, Josef S., et al.
Publicado: (2020)

Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2
por: Genovese, Mark C, et al.
Publicado: (2018)

Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry
por: Lockshin, Benjamin, et al.
Publicado: (2022)

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial
por: Blauvelt, A., et al.
Publicado: (2020)

Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-naïve Patients With Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results From the Randomized SPIRIT-H2H Trial
por: Reich, Kristian, et al.
Publicado: (2022)

Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes
por: Egeberg, Alexander, et al.
Publicado: (2023)

Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results
por: Deodhar, Atul A., et al.
Publicado: (2021)

Ixekizumab improves sleep and work productivity in patients with non-radiographic axial spondyloarthritis: results from the COAST-X trial at 52 weeks
por: Deodhar, Atul, et al.
Publicado: (2021)

Ixekizumab for the Treatment of Psoriasis: A Review of Phase III Trials
por: Farahnik, Benjamin, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_h1i8ed492db27rpb8qfp2mfvkn